A norepinephrine-dependent mechanism in the preoptic/anterior hypothalamic area but not in the mediobasal hypothalamus is involved in the regulation of the gonadotropin-releasing hormone pulse generator in ovariectomized rats.
Pulsatile gonadotropin secretion from the pituitary is dependent upon the gonadotropin-releasing hormone (Gn-RH) pulse generator producing intermittent release of the neuropeptide into the portal vessels. Various neurotransmitters seem to be involved in the regulation of pulsatile Gn-RH release. The present study was an attempt to determine in vivo the temporal relation of preoptic/anterior hypothalamic area (PO/AH) norepinephrine (NE) release and pulsatile luteinizing hormone (LH) secretion in ovariectomized rats. To assess whether NE acts in the PO/AH to maintain pulsatile Gn-RH release, we applied locally an alpha 1-receptor antagonist into this structure. Push-pull cannulae (PPC) were implanted into the PO/AH of ovariectomized rats. The contralateral, not PPC-implanted PO/AH was lesioned electrochemically. Another group of ovariectomized rats was implanted with a PPC into the mediobasal hypothalamus. Two experiments were performed: (1) To determine whether the PO/AH or the mediobasal hypothalamus is the site where NE exerts its stimulatory effect on LH secretion, we applied doxazosine, a new specific alpha 1-receptor antagonist, locally into these structures by means of PPC. The effect of this adrenergic drug on the Gn-RH pulse generator was examined by measuring blood LH levels. (2) To study the temporal relation between in vivo release rates of NE and amine metabolites in the preoptic area and pulsatile pituitary LH secretion, preoptic perfusates and blood samples were collected at 5-min intervals. Brain perfusates were subjected to high-performance liquid chromatography-electrochemical analysis. In blood samples LH concentrations were determined.(ABSTRACT TRUNCATED AT 250 WORDS)
Jarry
H
H
Department of Obstetrics and Gynecology, University of Göttingen, FRG.
Leonhardt
S
S
Wuttke
W
W
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D017292:Doxazosin; D005260:Female; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007031:Hypothalamus / Q000502:physiology*; D007032:Hypothalamus, Anterior / Q000502:physiology; D007033:Hypothalamus, Middle / Q000502:physiology; D007986:Luteinizing Hormone / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism / Q000502:physiology*; D010053:Ovary / Q000502:physiology*; D010906:Pituitary Hormone-Releasing Hormones / Q000378:metabolism*; D011224:Prazosin / Q000031:analogs & derivatives / Q000494:pharmacology; D011301:Preoptic Area / Q000502:physiology; D051381:Rats; D012636:Secretory Rate
D000317:Adrenergic alpha-Antagonists; D010906:Pituitary Hormone-Releasing Hormones; D015102:3,4-Dihydroxyphenylacetic Acid; D006897:Hydroxyindoleacetic Acid; D007986:Luteinizing Hormone; D017292:Doxazosin; D009638:Norepinephrine; D011224:Prazosin